Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 6/20 | 0.51 |
| ▸ | CTSL | P07711 | 5/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27337756 | 0.95 | CTSS (0.49) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL24766461 | 0.82 | PSMB5 (0.54) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL25148526 | 0.82 | CTSS (0.53) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL27101824 | 0.82 | CTSS (0.53) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL27332710 | 0.82 | AKT1 (0.47) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL13886178 | 0.82 | PSMB5 (0.61) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL25773989 | 0.81 | CTSS (0.52) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL25100478 | 0.81 | PSMB5 (0.46) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL27332708 | 0.80 | AKT1 (0.46) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL27332696 | 0.80 | AKT1 (0.46) | PSMB5CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | MABPLEX INTERNATIONAL CO., LTD (CN) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | DARS1, CD2, FCGR2A | PSMB5 1476/4885CTSS 3288/4885CTSL 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.